Nordic Capital ups Nycomed Pharma stake to 98%

Investee Company – Nycomed Pharma (Denmark)

Investee Company Business Type – Generic prescription medicine developer

Type of Financing – Acquisition capital

Equity Providers – Nordic Capital

Equity Leader (Individual) – Bo Soderberg and Toni Weitzberg.

Debt Providers – N/A

Debt Type – N/A

Debt Leader (Individual) – N/A

Equity Amount – Undisclosed Investment

Total Deal Value – Undisclosed

Other Advisors – No Advisors employed

Comments – Nycomed Pharma is a pharmaceutical company based in Roskilde, Denmark. It active in the development, manufacturing, marketing and sales, of both patented and branded generic prescription medicines, over-the-counter pharmaceuticals and consumer healthcare products. In 2000 it had a turnover of approximately euro462 million.

Nordic Capital has reached an agreement with Amersham to acquire its 29% stake in Nycomed Pharma for an undisclosed sum. Nordic Capital already had a majority share holding in the company but having acquired Amersham’s stake, now owns 98% of Nycomed Pharma.

Toni Weitzberg, who is chairman of Nycomed Pharma and a partner at Nordic Capital, said: “We are pleased with our co-operation with Amersham since 1999. From now we will take the full responsibility of developing Nycomed Pharma in the future. Our increased investment will further strengthen Nordic Capital’s position as a leading European private firm in the healthcare area.”